Cervical Cancer and Tumor Growth Assessment
Author Information
Author(s): D.C. Brown, D. Cole, K.C. Gatter, D.Y. Mason
Primary Institution: Nuffield Department of Pathology, John Radcliffe Hospital, Oxford
Hypothesis
Can the monoclonal antibody Ki67 be used to assess tumor cell proliferation rates in cervical carcinoma biopsies?
Conclusion
The study found a wide variation in tumor cell proliferation rates in cervical carcinoma, but no significant relationship with tumor grade or type.
Supporting Evidence
- The study observed a range of 10-50% in Ki67 staining among cervical carcinoma samples.
- There was no significant relationship between Ki67 staining and conventional histological parameters.
- Immunostaining with Ki67 provides a new approach to assessing cervical tumor biopsies.
Takeaway
Doctors looked at samples from women with cervical cancer to see how fast the cancer cells were growing. They found that some grew faster than others, but it didn't seem to depend on the type of cancer.
Methodology
Immunohistochemical staining of cervical biopsies with Ki67 to assess tumor cell proliferation rates.
Limitations
The study was limited to biopsy material and did not include long-term clinical follow-up data.
Participant Demographics
31 patients with invasive cervical carcinoma, including both adenocarcinoma and squamous carcinoma.
Want to read the original?
Access the complete publication on the publisher's website